e-learning
resources
Milan 2017
Sunday, 10.09.2017
COPD management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine).
R. Dal Negro (Verona, Vr, Italy)
Source:
International Congress 2017 – COPD management
Session:
COPD management
Session type:
Thematic Poster
Number:
675
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Dal Negro (Verona, Vr, Italy). Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine).. 675
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study
Source: Eur Respir J, 50 (4) 1700711; 10.1183/13993003.00711-2017
Year: 2017
Erdosteine oral treatment of hospitalised COPD exacerbation prolongs time to first re-exacerbation
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Prediction of the duration of hospitilization in acute COPD exacerbations: The AECOPD-F score
Source: International Congress 2014 – Monitoring COPD with different biomarkers
Year: 2014
Estimation of tiotropium efficacy at the COPD patients with group D
Source: International Congress 2015 – Different data in COPD
Year: 2015
Microbiome Use to Stratify Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (MUSIC) trial: baseline data and impact of inhaled corticosteroid withdrawal in severe COPD with frequent exacerbations
Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils
Year: 2020
Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on exacerbations in moderate-to-severe COPD: Pooled analysis of two studies
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
LATE-BREAKING ABSTRACT: Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014
Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: Pooled analysis of phase III studies
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
LATE-BREAKING ABSTRACT: beta-blockers are associated with a reduction in COPD exacerbations in COPDGene
Source: International Congress 2014 – COPD exacerbations
Year: 2014
Positive outcomes of 900 mg daily erdosteine in acute exacerbation of COPD
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Treatment failure of hospitalized patients with COPD exacerbation using systemic corticosteroids plus antibiotics: Role of early inflammatory predictors
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Impact of mucolytic treatment on COPD exacerbations
Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation
Year: 2013
The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Impact of halotherapy on COPD exacerbations
Source: International Congress 2019 – COPD treatment: cohorts and real-world studies
Year: 2019
Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy
Source: International Congress 2015 – Advances in the future treatment of COPD
Year: 2015
Effects of ambient temperature on COPD symptoms and exacerbations in the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) cohort
Source: Virtual Congress 2021 – Environment and respiratory health
Year: 2021
Long term treatment with n-acetylcysteine reduces exacerbations in moderate chronic obstructive pulmonary disease
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept